ANDREA SPURLING: Open Payments
NPI 1922314863 · MAGNOLIA, AR. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$512 in 26 payments from 11 companies in 2025. Trend: 2023 $820 · 2024 $927 · 2025 $512
Food & beverage: $512
| Company | Payments | Amount |
|---|---|---|
| AstraZeneca Pharmaceuticals LP | 5 | $105 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 3 | $80 |
| Novo Nordisk Inc | 3 | $57 |
| GlaxoSmithKline, LLC. | 3 | $49 |
| ABBVIE INC. | 2 | $47 |
| Abbott Laboratories | 2 | $46 |
| Lilly USA, LLC | 3 | $46 |
| Takeda Pharmaceuticals U.S.A., Inc. | 2 | $35 |
| PFIZER INC. | 1 | $17 |
| Astellas Pharma US Inc | 1 | $16 |
Products named: CAPLYTA, FARXIGA, TRELEGY ELLIPTA, FREESTYLE LIBRE 3, MOUNJARO, BREZTRI, Rybelsus, TRINTELLIX.
Industry payments across AR — which companies pay providers there.
